The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397).
AuthorsStephens, Richard J
Dearnaley, David P
Cowan, Richard A
Sydes, Matthew R
Fallowfield, Lesley J
AffiliationCancer Group, MRC Clinical Trials Unit, London, UK. firstname.lastname@example.org
MetadataShow full item record
AbstractOBJECTIVE: To explore patients' quality of life (QoL) during neoadjuvant hormone therapy (HT) using data from the Medical Research Council RT01 trial of standard- (64 Gy/32-fraction) and high- (74 Gy/37-fraction) dose radiotherapy (RT, both given conformally). PATIENTS AND METHODS: Of the 843 patients randomized to the RT01 trial, 316 completed the Functional Assessment Of Cancer Therapy core questionnaire with its additional prostate subscale, and the Short Form-36 Health Survey questionnaire with the University of California-Los Angeles Prostate Cancer Index before HT and again before starting RT. Three predefined QoL hypotheses were generated to focus the analyses. RESULTS: For the three primary QoL analyses there was evidence that sexual functioning deteriorated, urinary function did not change, and there was a slight decline in physical well-being after > or = 3 months of HT. Sensitivity analyses confirmed these findings. Exploratory analyses also suggested that role functioning deteriorated, sleep was more disturbed, and there was an increase in fatigue. However, overall QoL was not reported to be affected and patients indicated an improvement in attitude and satisfaction with treatment. CONCLUSIONS: In this group of men, many of whom reported reduced sexual functioning before treatment, the additional decline during HT seemed to be generally accepted as the price to pay for an appropriate cancer treatment. Nevertheless, these changes need to be discussed with patients before HT is commenced.
CitationThe quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397). 2007, 99 (2):301-10 BJU Int.
- Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
- Authors: Denham JW, Wilcox C, Joseph D, Spry NA, Lamb DS, Tai KH, Matthews J, Atkinson C, Turner S, Christie D, Gogna NK, Kenny L, Duchesne G, Delahunt B, McElduff P
- Issue date: 2012 Dec
- Survivorship after prostate cancer treatment: spouses' quality of life at 36 months.
- Authors: Harden J, Sanda MG, Wei JT, Yarandi HN, Hembroff L, Hardy J, Northouse L
- Issue date: 2013 Nov
- Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy.
- Authors: Truong PT, Berthelet E, Lee JC, Petersen R, Lim JT, Gaul CA, Pai H, Blood P, Ludgate CM
- Issue date: 2006 Jun
- Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
- Authors: Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C
- Issue date: 2011 May
- Does neoadjuvant hormone therapy for early prostate cancer affect cognition? Results from a pilot study.
- Authors: Jenkins VA, Bloomfield DJ, Shilling VM, Edginton TL
- Issue date: 2005 Jul